Comparative Pharmacology
Head-to-head clinical analysis: CHLOROMYXIN versus SYNERCID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOROMYXIN versus SYNERCID.
CHLOROMYXIN vs SYNERCID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chloromyxin is a combination product of chloramphenicol and polymyxin B. Chloramphenicol inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation. Polymyxin B disrupts bacterial cell membrane integrity by interacting with lipopolysaccharides in gram-negative bacteria.
Synercid is a combination of two streptogramin antibiotics, quinupristin and dalfopristin, which bind to the 50S bacterial ribosome and inhibit protein synthesis. Quinupristin binds to the 23S rRNA near the peptidyl transferase center, while dalfopristin binds to a nearby site and enhances quinupristin's binding. The synergistic effect results in irreversible inhibition of bacterial protein synthesis.
500 mg IV every 6 hours or 1 g IV every 12 hours; infusion over 30 minutes.
7.5 mg/kg IV every 8 hours, administered as a 60-minute infusion.
None Documented
None Documented
CHLOROMYXIN is not a recognized drug. No data available.
The terminal elimination half-life is approximately 0.85 hours for dalfopristin and 1.3 hours for quinupristin; however, the active metabolite of quinupristin has a half-life of about 3.5 hours, supporting twice-daily dosing.
CHLOROMYXIN is not a recognized drug. No data available.
Primarily hepatic metabolism with biliary excretion; approximately 15% of the dalfopristin dose and 32% of the quinupristin dose are excreted unchanged in feces; renal excretion is minor (<5% for both components).
Category C
Category C
Antibiotic
Antibiotic